SK279535B6 - Ľudský imunitný interferón a jeho derivát, izolát - Google Patents

Ľudský imunitný interferón a jeho derivát, izolát Download PDF

Info

Publication number
SK279535B6
SK279535B6 SK7389-82A SK738982A SK279535B6 SK 279535 B6 SK279535 B6 SK 279535B6 SK 738982 A SK738982 A SK 738982A SK 279535 B6 SK279535 B6 SK 279535B6
Authority
SK
Slovakia
Prior art keywords
human immune
immune interferon
interferon
dna
amino acid
Prior art date
Application number
SK7389-82A
Other languages
English (en)
Slovak (sk)
Other versions
SK738982A3 (en
Inventor
David V. Goeddel
Patrick W. Gray
Original Assignee
Genentech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23211703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK279535(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech filed Critical Genentech
Publication of SK738982A3 publication Critical patent/SK738982A3/sk
Publication of SK279535B6 publication Critical patent/SK279535B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/811—Interferon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/30—Signal or leader sequence
SK7389-82A 1981-10-19 1982-10-18 Ľudský imunitný interferón a jeho derivát, izolát SK279535B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31248981A 1981-10-19 1981-10-19

Publications (2)

Publication Number Publication Date
SK738982A3 SK738982A3 (en) 1998-12-02
SK279535B6 true SK279535B6 (sk) 1998-12-02

Family

ID=23211703

Family Applications (1)

Application Number Title Priority Date Filing Date
SK7389-82A SK279535B6 (sk) 1981-10-19 1982-10-18 Ľudský imunitný interferón a jeho derivát, izolát

Country Status (43)

Country Link
US (4) US4762791A (xx)
EP (1) EP0077670B1 (xx)
JP (3) JPS5890514A (xx)
KR (1) KR840001837A (xx)
AT (1) ATE44289T1 (xx)
AU (1) AU561343B2 (xx)
BG (2) BG44877A3 (xx)
BR (1) BR8206068A (xx)
CA (1) CA1341590C (xx)
CH (1) CH663619A5 (xx)
CZ (1) CZ282154B6 (xx)
DD (1) DD208822A5 (xx)
DE (4) DE3238554A1 (xx)
DK (1) DK163187C (xx)
DZ (1) DZ467A1 (xx)
ES (1) ES516620A0 (xx)
FI (1) FI86559C (xx)
FR (1) FR2514783B1 (xx)
GB (1) GB2107718B (xx)
GR (1) GR78391B (xx)
GT (1) GT198277746A (xx)
HK (1) HK66289A (xx)
HU (1) HU202287B (xx)
IE (1) IE54371B1 (xx)
IL (1) IL66992A (xx)
IT (1) IT1153265B (xx)
LU (1) LU88327I2 (xx)
MX (2) MX166499B (xx)
MY (1) MY102546A (xx)
NL (1) NL930040I2 (xx)
NO (2) NO164177C (xx)
NZ (1) NZ202190A (xx)
OA (1) OA07233A (xx)
PH (1) PH26963A (xx)
PL (1) PL153202B1 (xx)
PT (1) PT75696B (xx)
RO (1) RO89534A (xx)
RU (3) RU2056460C1 (xx)
SG (1) SG76988G (xx)
SK (1) SK279535B6 (xx)
YU (1) YU45871B (xx)
ZA (1) ZA827569B (xx)
ZW (1) ZW22282A1 (xx)

Families Citing this family (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
ZW18282A1 (en) * 1981-08-31 1983-03-23 Genentech Inc Preparation of polypeptides in vertebrate cell culture
JPS58146281A (ja) * 1981-10-19 1983-08-31 Suntory Ltd 酵母細胞の形質転換法
AU561343B2 (en) * 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
JPS58110548A (ja) * 1981-12-24 1983-07-01 Asahi Chem Ind Co Ltd 新規な生理活性ペプチド
JPS62223191A (ja) * 1981-12-24 1987-10-01 Asahi Chem Ind Co Ltd 新規な生理活性ペプチドの製法
GB8406910D0 (en) * 1984-03-16 1984-04-18 Biogen Nv Gamma interferon
ZA831094B (en) * 1982-02-22 1983-11-30 Biogen Nv Dna sequences,recombinant dna molecules and processes for producing human immune interferon-like polypeptides
US5004689A (en) * 1982-02-22 1991-04-02 Biogen, Massachusetts DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields
US6432677B1 (en) 1982-03-08 2002-08-13 Genentech, Inc. Non-human animal interferons
IE54592B1 (en) * 1982-03-08 1989-12-06 Genentech Inc Anumal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and espression vehicles containing such sequences and cells transformed thereby
US5827694A (en) * 1982-03-08 1998-10-27 Genentech, Inc. DNA encoding non-human animal interferons, vectors and hosts therefor, and recombinant production of IFN polypeptides
IL68100A0 (en) * 1982-03-24 1983-06-15 Takeda Chemical Industries Ltd Novel dna and use thereof
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
JPH0787797B2 (ja) * 1982-05-20 1995-09-27 サントリー株式会社 ヒト・ガンマ・インタ−フエロン様ポリペプチドの製造法
AU577259B2 (en) * 1982-08-13 1988-09-22 Zymogenetics Inc. Glycolytic promters for regulated protein expression protease inhibitor
AU571460B2 (en) * 1982-09-27 1988-04-21 Cancer Institute Of Japanese Foundation For Cancer Research Alpha interferon dna, recombinant plasmid, engineered organism and alpha interferon polypeptide
EP0121569B1 (en) * 1982-10-08 1990-08-22 Kyowa Hakko Kogyo Co., Ltd. Novel vector
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US5831023A (en) * 1982-11-01 1998-11-03 Genentech, Inc. Recombinant animal interferon polypeptides
WO1984002129A1 (en) * 1982-11-22 1984-06-07 Takeda Chemical Industries Ltd Human immune interferon protein and process for its preparation
US4599197A (en) * 1982-12-22 1986-07-08 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4512922A (en) * 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4518526A (en) * 1982-12-22 1985-05-21 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4620948A (en) * 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
GR79124B (xx) * 1982-12-22 1984-10-02 Genentech Inc
JPH0740925B2 (ja) * 1983-03-14 1995-05-10 協和醗酵工業株式会社 新規ヒトインタ−フエロン−γポリペプチド
US7198919B1 (en) * 1983-04-25 2007-04-03 Genentech, Inc. Use of alpha factor sequences in yeast expression systems
ZA843275B (en) * 1983-05-05 1984-12-24 Hoffmann La Roche Novel vectors for interferon expression
DK265384A (da) * 1983-06-01 1984-12-02 Hoffmann La Roche Polypeptider med interferonaktivitet
JP2551746B2 (ja) * 1983-07-19 1996-11-06 サントリー株式会社 改良プラスミドベクタ−およびその利用
JPS6034919A (ja) * 1983-08-04 1985-02-22 Green Cross Corp:The ガンマ・インタ−フェロン組成物
DE3484374D1 (de) * 1983-08-04 1991-05-08 Green Cross Corp Gamma-interferonzusammensetzung.
IL72773A0 (en) * 1983-08-29 1984-11-30 Meloy Lab Production of immune interferon and its mrna
US4681930A (en) * 1983-09-20 1987-07-21 Hoffmann-La Roche Inc. Immune interferon and a method for its extraction and purification
US4604284A (en) * 1983-09-20 1986-08-05 Hoffmann-La Roche Inc. Homogeneous immune interferon fragment
ZA846554B (en) * 1983-09-20 1985-04-24 Hoffmann La Roche Immune interferon and method for its purification
US4476049A (en) * 1983-09-20 1984-10-09 Hoffmann-La Roche Inc. Method for the extraction of immune interferon
JPS6079000A (ja) * 1983-10-04 1985-05-04 Takeda Chem Ind Ltd ヒトγ型インタ−フエロン単量体の製造法
JPH0788398B2 (ja) * 1983-10-17 1995-09-27 サントリー株式会社 新規生理活性ポリペプチドおよびその製造法
GB8328820D0 (en) * 1983-10-28 1983-11-30 Searle & Co Synthetic human gamma interferon gene
FR2556365B1 (fr) * 1983-12-09 1987-07-31 Transgene Sa Vecteurs de clonage et d'expression de l'interferon-g, bacteries transformees et procede de preparation de l'interferon-g
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
MX9203641A (es) * 1983-12-16 1992-07-01 Genentech Inc Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion.
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
JPS60145098A (ja) * 1984-01-09 1985-07-31 Suntory Ltd 糖付加ポリペプチドの製造法
WO1985004420A1 (en) * 1984-03-29 1985-10-10 Takeda Chemical Industries, Ltd. Novel dna and its use
DE3414831A1 (de) * 1984-04-19 1985-10-31 Hoechst Ag, 6230 Frankfurt Herstellung von polypeptiden mit human-gammainterferon-aktivitaet
GB8414354D0 (en) * 1984-06-05 1984-07-11 Biogen Nv Purifying protein
IL75302A0 (en) * 1984-06-06 1985-09-29 Takeda Chemical Industries Ltd Novel polypeptide and production thereof
WO1985005618A1 (en) * 1984-06-06 1985-12-19 Takeda Chemical Industries, Ltd. Process for preparing interferon derivative
CA1302320C (en) * 1984-06-11 1992-06-02 Hideo Niwa Expression of human cromosomal interferon-_ in animal cells
JPS60262594A (ja) * 1984-06-11 1985-12-25 Kanegafuchi Chem Ind Co Ltd ヒトインタ−フエロン−γ
GB8414911D0 (en) * 1984-06-12 1984-07-18 Searle & Co Producing human gamma interferon
JPS6124599A (ja) * 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd 新規ヒトインタ−フエロン−ｒポリペプチド誘導体
GB2164650A (en) * 1984-09-25 1986-03-26 Fujisawa Pharmaceutical Co Process for production of y-interferon
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
JPS6188875A (ja) * 1984-10-05 1986-05-07 Kanegafuchi Chem Ind Co Ltd ヒトインタ−フエロン−γ
ATE66375T1 (de) * 1984-10-05 1991-09-15 Bioferon Biochem Substanz Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von verschiedenen erkrankungen des menschen in niedriger dosierung.
DE3436638C2 (de) * 1984-10-05 1992-10-08 Bioferon biochemische Substanzen GmbH & Co, 7958 Laupheim Verwendung von Interferon-gamma (IFN-gamma) enthaltenden Präparationen zur Behandlung rheumatischer Erkrankungen
US4946674A (en) * 1984-10-05 1990-08-07 Bioferon Biochemische Substanzen Gmbh & Co. Process for treatment of rheumatic diseases
JPS61108397A (ja) * 1984-10-31 1986-05-27 Green Cross Corp:The インタ−フエロン−γ蛋白質の製造法
AU598455B2 (en) * 1984-12-27 1990-06-28 Suntory Limited Method for purifying an interferon
JPS6156195A (ja) * 1985-03-01 1986-03-20 Asahi Chem Ind Co Ltd 新規生理活性ペプチド
GB8508340D0 (en) * 1985-03-29 1985-05-09 Creighton T E Production of protein
WO1986006077A1 (en) * 1985-04-08 1986-10-23 Amgen A method and a hybrid promoter for controlling exogenous gene transcription
US4873312A (en) * 1985-04-25 1989-10-10 Amgen Method for purifying interferon and composition of matter produced thereby
FR2583429B1 (fr) * 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
US4845196A (en) * 1985-06-24 1989-07-04 G. D. Searle & Co. Modified interferon gammas
EP0245479B1 (en) * 1985-11-13 1993-02-17 Xoma Corporation Shortened phosphoglycerate kinase promoter
US5104795A (en) * 1985-11-13 1992-04-14 Zoma Corporation Shortened phosphoglycerate kinase promoter
EP0237019A3 (en) * 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
US5198343A (en) * 1986-08-05 1993-03-30 Transgene, S.A. Method for expressing a heterologous protein in a dapD- mutant of E. coli and the strain obtained
US6238889B1 (en) * 1986-12-16 2001-05-29 Dsm N.V. Molecular cloning and expression of the Pro8 isoform of human IL-3
US4939088A (en) * 1987-02-18 1990-07-03 Meloy Laboratories Inc. Sustained production of recombinant gamma interferon using an Epstein-Barr virus replicon
US4944941A (en) * 1987-08-07 1990-07-31 Genentech, Inc. Methods and compositions for the treatment of lung conditions
US6384194B1 (en) * 1987-12-16 2002-05-07 Dsm N.V. Expression and purification of human interleukin-3 and muteins thereof
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
IL90021A0 (en) * 1988-04-25 1989-12-15 Phillips Petroleum Co Process for the production of interferon
US5198212A (en) * 1988-10-31 1993-03-30 University Of Lousville Research Foundation Incorporated Method and compositions for treatment of trauma-associated sepsis with gamma interferon
US6451600B1 (en) * 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US20020168750A1 (en) * 1988-12-23 2002-11-14 James Rasmussen Enzymatically active recombinant glucocerebrosidase
US5236838A (en) * 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5196191A (en) * 1989-03-17 1993-03-23 Genentech, Inc. Temporal gamma-interferon administration for allergies
US5112605A (en) * 1989-03-17 1992-05-12 Genentech, Inc. Temporal gamma-interferon administration for allergies
WO1990012877A1 (en) * 1989-04-19 1990-11-01 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
DE4009268A1 (de) * 1990-03-22 1991-09-26 Consortium Elektrochem Ind Sekretion von hirudinderivaten
US5281520A (en) * 1990-09-12 1994-01-25 Zymogenetics, Inc. Method for producing acyloxyacyl hydrolase
ATE132162T1 (de) * 1990-09-27 1996-01-15 Schering Corp Humane gammainterferonantagonisten
EP0487298A3 (en) * 1990-11-21 1992-12-16 Schering Corporation Human gamma interferon antagonist/agonist screen
WO1992012238A1 (en) * 1991-01-04 1992-07-23 The Board Of Regents, University Of Texas System Cloning and expression of tissue transglutaminases
US5272078A (en) * 1991-01-29 1993-12-21 Brigham And Women's Hospital CDNA encoding the type I iodothyronine 5'deiodinase
AU1337092A (en) * 1991-01-29 1992-08-27 Brigham And Women's Hospital A cdna encoding the type i iodothyronine 5' deiodinase
WO1994003599A1 (en) * 1992-08-04 1994-02-17 Sagami Chemical Research Center HUMAN cDNA AND PROTEIN WHICH SAID cDNA CODES FOR
US6180602B1 (en) 1992-08-04 2001-01-30 Sagami Chemical Research Center Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent
WO1994010296A1 (en) * 1992-11-03 1994-05-11 Oklahoma Medical Research Foundation Transglutaminase gene
DE69322289T2 (de) * 1992-12-29 1999-05-20 Genentech Inc Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
EP0814154B1 (en) 1993-09-15 2009-07-29 Novartis Vaccines and Diagnostics, Inc. Recombinant alphavirus vectors
JP4383530B2 (ja) 1996-04-05 2009-12-16 ノバルティス バクシンズ アンド ダイアグノスティックス， インコーポレーテッド 細胞巨大分子合成の阻害が減少したアルファウイルスベクター
EP0935659A1 (en) 1996-09-17 1999-08-18 Chiron Corporation Compositions and methods for treating intracellular diseases
US20020168634A1 (en) * 1999-05-05 2002-11-14 Christine Marie Debouck Methods for identifiying genes essential to the growth of an organism
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
BR9812267B1 (pt) 1997-07-14 2013-11-26 Hormônio de crescimento recombinante.
AU757910B2 (en) 1998-04-02 2003-03-13 Genentech Inc. Treatment of cardiac hypertrophy
JP2002533124A (ja) 1998-12-31 2002-10-08 カイロン コーポレイション Ｈｉｖポリペプチドの改善された発現およびウイルス様粒子の生成
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
KR20020065517A (ko) 1999-11-12 2002-08-13 맥시겐 홀딩스 리미티드 인터페론 감마 접합체
YU32402A (sh) 1999-11-12 2005-03-15 Maxygen Holdings Ltd. Konjugati gama interferona
CA2405912A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
ATE367398T1 (de) * 2000-05-16 2007-08-15 Bolder Biotechnology Inc Verfahren zur rückfaltung von proteinen mit freien cysteinresten
AU2002225870B2 (en) * 2000-11-03 2006-09-21 Intarcia Therapeutics, Inc. Method for short-term and long-term drug dosimetry
CN101612402A (zh) * 2001-01-09 2009-12-30 贝勒研究院 干扰素拮抗剂和Flt3L拮抗剂的用途
US7038015B2 (en) 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
CA2452119C (en) 2001-07-05 2013-10-15 Chiron Corporation Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
WO2003004620A2 (en) 2001-07-05 2003-01-16 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CN1604795B (zh) * 2001-08-17 2010-05-26 科勒制药股份公司 具有提高的活性的组合基序免疫刺激寡肽
JP2005509647A (ja) * 2001-11-06 2005-04-14 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ エストロゲン応答性乳癌の治療方法
JP2005511580A (ja) * 2001-11-06 2005-04-28 アプライド・リサーチ・システムズ・エーアールエス・ホールディング・エヌ・ヴィ 子宮内膜症の処置法
KR20040053291A (ko) * 2001-11-09 2004-06-23 바이오메디신즈 인코포레이티드 오메가 인터페론을 이용한 질환 치료 방법
WO2003049760A1 (en) * 2001-12-07 2003-06-19 Intermune, Inc. Compositions and method for treating hepatitis virus infection
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
AU2003228751A1 (en) 2002-05-01 2003-11-17 Cell Genesys, Inc. Lentiviral vector particles resistant to complement inactivation
EP1539814A2 (en) 2002-07-03 2005-06-15 Maxygen Holdings Ltd. c/o Close Brothers (Cayman) Limited Full-length interferon gamma polypeptide variants
US7229614B2 (en) * 2002-07-03 2007-06-12 The Brigham And Women's Hospital, Inc. Interferon gamma in the detection and treatment of angiomyolipomas
WO2004034988A2 (en) * 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP2008504002A (ja) 2003-11-12 2008-02-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド 新生児Ｆｃレセプター（ＦｃＲｎ）結合ポリペプチド改変体、ダイマーＦｃ結合タンパク質、およびそれらに関連する方法
NZ586034A (en) 2004-02-02 2011-10-28 Ambrx Inc Modified human growth hormone polypeptides and their uses
WO2006050394A2 (en) 2004-11-01 2006-05-11 Novartis Vaccines And Diagnostics Inc. Combination approaches for generating immune responses
JP2008525424A (ja) 2004-12-23 2008-07-17 モルメド エスピーエー 複合生成物
JP2008526234A (ja) 2005-01-05 2008-07-24 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｃｒｉｐｔｏ結合分子
DK1848744T3 (da) * 2005-01-27 2012-03-19 Novimmune Sa Humane anti-interferon-gamma-antistoffer og fremgangsmåder til anvendelse heraf
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
JP5143131B2 (ja) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
WO2008076933A2 (en) 2006-12-14 2008-06-26 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
NZ580686A (en) * 2007-05-02 2012-11-30 Ambrx Inc Modified interferon beta polypeptides and their uses
US20090155838A1 (en) * 2007-11-28 2009-06-18 Smart Tube, Inc. Devices, systems and methods for the collection, stimulation, stabilization, and analysis of a biological sample
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
EP2248903A1 (en) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
NZ598686A (en) 2009-09-28 2014-05-30 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
EA201291482A1 (ru) 2010-07-09 2013-10-30 Байоджен Айдек Хемофилия Инк. Химерные факторы коагуляции
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
RU2446172C1 (ru) * 2011-03-24 2012-03-27 Общество С Ограниченной Ответственностью "Фармапарк" Способ получения зрелого интерферона альфа-2 человека с использованием дрожжей saccharomyces cerevisiae и штамм-продуцент интерферона альфа-2 человека (варианты)
EA023379B1 (ru) * 2011-06-21 2016-05-31 Общество С Ограниченной Ответственностью "Фарма Ген" ШТАММ ESCHERICHIA COLI BL21(DE3)-pIE-GAMMA И СПОСОБ ПОЛУЧЕНИЯ ПРЕПАРАТА НАТИВНОГО РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА ГАММА ЧЕЛОВЕКА
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
BR112014016887A2 (pt) 2012-01-10 2018-08-14 Biogen Idec Inc potencialização do transporte de moléculas terapêu-ticas através da barreira hematoencefálica
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
EP2870238A4 (en) 2012-07-05 2016-03-09 Ohio State Innovation Foundation COMPOSITIONS AND METHODS ASSOCIATED WITH VIRAL VACCINES
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN107636159B (zh) 2015-02-04 2022-06-14 百时美施贵宝公司 选择治疗性分子的方法
MA41586A (fr) 2015-02-04 2017-12-13 Hoffmann La Roche Oligomères antisens de la protéine tau et leurs utilisations
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
AU2016257023B2 (en) 2015-05-07 2022-06-30 Swedish Orphan Biovitrum Ag Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkers
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
US11324816B2 (en) 2015-08-31 2022-05-10 Technovax, Inc. Human respiratory syncytial virus (HRSV) virus-like particles (VLPS) based vaccine
WO2017180770A1 (en) 2016-04-13 2017-10-19 Synthetic Genomics, Inc. Recombinant arterivirus replicon systems and uses thereof
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3526332A1 (en) 2016-10-17 2019-08-21 Synthetic Genomics, Inc. Recombinant virus replicon systems and uses thereof
BR112019011661A2 (pt) 2016-12-05 2020-01-07 Synthetic Genomics, Inc. Composições e métodos para aumentar expressão de gene
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
AU2019210189A1 (en) 2018-01-19 2020-08-06 Janssen Pharmaceuticals, Inc. Induce and enhance immune responses using recombinant replicon systems
IL296520A (en) 2020-03-19 2022-11-01 Trizell Ltd A virus storage system that responds to temperature
JP2023519709A (ja) 2020-03-30 2023-05-12 トライゼル リミテッド がんを治療するための組成物及び方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4332892A (en) * 1979-01-15 1982-06-01 President And Fellows Of Harvard College Protein synthesis
JPS5598118A (en) * 1979-01-18 1980-07-25 Hayashibara Takeshi Preparation of type-2 interferon and drug containing the same
AU538665B2 (en) * 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
IL58765A (en) * 1979-11-21 1986-09-30 Yeda Res & Dev Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta
GB2068970B (en) * 1980-02-06 1983-06-22 Searle & Co Recombinant dna technique for the preparation of a protein resembling human interferon
DE3005897A1 (de) * 1980-02-16 1981-09-03 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4460685A (en) * 1980-05-29 1984-07-17 New York University Method of enhancing the production of human γ Interferon
FI64813C (fi) * 1980-12-31 1984-01-10 Ilkka Antero Palva Foerfarande foer producering av ett utvalt aeggviteaemne och vid foerfarandet anvaenda rekombinantplasmidvektorer
IL65475A0 (en) * 1981-04-17 1982-07-30 Meloy Lab Production of immune interferon and its mrna
US4376821A (en) * 1981-04-17 1983-03-15 Meloy Laboratories, Inc. Production of human IFN-gamma (immune) interferon
AU561343B2 (en) * 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna

Also Published As

Publication number Publication date
HU202287B (en) 1991-02-28
ZA827569B (en) 1983-11-30
KR840001837A (ko) 1984-06-07
BG42527A3 (en) 1987-12-15
IL66992A0 (en) 1983-02-23
ZW22282A1 (en) 1983-05-11
NO1994025I1 (no) 1994-12-20
BG44877A3 (xx) 1989-02-15
PT75696A (en) 1982-11-01
FI823528L (fi) 1983-04-20
JPH03246232A (ja) 1991-11-01
CA1341590C (en) 2009-02-03
GT198277746A (es) 1984-04-11
NL930040I2 (nl) 1993-09-16
RU2107728C1 (ru) 1998-03-27
JPS5890514A (ja) 1983-05-30
ES8402351A1 (es) 1984-02-01
ATE44289T1 (de) 1989-07-15
US4925793A (en) 1990-05-15
YU45871B (sh) 1992-09-07
HK66289A (en) 1989-08-25
DE3279788D1 (en) 1989-08-03
CZ738982A3 (en) 1997-03-12
IE54371B1 (en) 1989-09-13
GB2107718A (en) 1983-05-05
NO164177B (no) 1990-05-28
NZ202190A (en) 1987-06-30
RU2092561C1 (ru) 1997-10-10
BR8206068A (pt) 1983-09-13
EP0077670A3 (en) 1984-07-04
CZ282154B6 (cs) 1997-05-14
FI823528A0 (fi) 1982-10-15
IT1153265B (it) 1987-01-14
DZ467A1 (fr) 2004-09-13
NO823467L (no) 1983-04-20
SG76988G (en) 1989-03-23
RO89534A (ro) 1986-07-30
AU561343B2 (en) 1987-05-07
IL66992A (en) 1991-07-18
IE822517L (en) 1983-04-19
GR78391B (xx) 1984-09-27
JPS62265986A (ja) 1987-11-18
DK460882A (da) 1983-05-27
DD208822A5 (de) 1984-04-11
NL930040I1 (nl) 1993-08-02
IT8223795A0 (it) 1982-10-18
EP0077670A2 (en) 1983-04-27
US4762791A (en) 1988-08-09
US4929554A (en) 1990-05-29
SK738982A3 (en) 1998-12-02
MY102546A (en) 1992-07-31
YU233582A (en) 1985-03-20
MX9206041A (es) 1994-04-29
FR2514783A1 (fr) 1983-04-22
CH663619A5 (de) 1987-12-31
JPH0135639B2 (xx) 1989-07-26
RU2056460C1 (ru) 1996-03-20
NO164177C (no) 1990-09-12
PL153202B1 (en) 1991-03-29
US4727138A (en) 1988-02-23
DE3238554C2 (xx) 1989-11-23
EP0077670B1 (en) 1989-06-28
LU88327I2 (fr) 1994-05-04
FI86559B (fi) 1992-05-29
PT75696B (en) 1987-03-24
DE77670T1 (de) 1987-09-03
DE3238554A1 (de) 1983-05-05
FR2514783B1 (fr) 1985-11-29
OA07233A (fr) 1984-04-30
MX166499B (es) 1993-01-12
PL238671A1 (en) 1983-07-18
FI86559C (fi) 1992-09-10
AU8935282A (en) 1983-04-28
JP2515308B2 (ja) 1996-07-10
DK163187B (da) 1992-02-03
GB2107718B (en) 1985-11-20
DK163187C (da) 1992-06-22
JPH07106144B2 (ja) 1995-11-15
PH26963A (en) 1992-12-28
DE19375065I2 (de) 2004-07-01
ES516620A0 (es) 1984-02-01

Similar Documents

Publication Publication Date Title
SK279535B6 (sk) Ľudský imunitný interferón a jeho derivát, izolát
US5096705A (en) Human immune interferon
US4853332A (en) Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US6610830B1 (en) Microbial production of mature human leukocyte interferons
US5582824A (en) Recombinant DES-CYS-TYR-CYS human immune interferon
CA2195799C (en) Bacterial production of hydrophobic polypeptides
EP0041313A2 (en) DNA sequences, recombinant DNA molecules and processes for producing human fibroblast interferon
JP2633227B2 (ja) 動物インターフエロン
EP0165654B1 (en) Purified interleukin 1
JPS6361920B2 (xx)
EP0546099B1 (en) Use of human Interferon gamma 4-134
WO1985005618A1 (en) Process for preparing interferon derivative
BG61060B2 (bg) човешки имунен интерферон
HRP950157A2 (en) Polypeptide with human interferon (ifn-gamma) characteristics
NZ214261A (en) Human immune interferon: production by recombinant dna technology
BG60939B2 (bg) човешки имунен интерферон
PH26492A (en) Recombinant human immune interferon
BG60889B2 (bg) човешки имунен интерферон
BG60888B2 (bg) човешки имунен интерферон
BG60890B2 (bg) човешки имунен интерферон